Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 9Prostatic Neoplasms 6Melanoma 6Colorectal Neoplasms 5Squamous Cell Carcinoma of Head and Neck 4Rectal Neoplasms 4Neoplasm Metastasis 4Multiple Myeloma 4Mouth Neoplasms 4Uterine Cervical Neoplasms 3Triple Negative Breast Neoplasms 3Neoplasms 3Head and Neck Neoplasms 3Colonic Neoplasms 3Uterine Cervical Dysplasia 2Skin Neoplasms 2Sarcoma, Kaposi 2Sarcoma 2Pancreatic Neoplasms 2Oropharyngeal Neoplasms 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Inflammatory Breast Neoplasms 2HIV Infections 2Uveal Melanoma 1Urinary Bladder Neoplasms 1Urinary Bladder Diseases 1Unspecified Adult Solid Tumor, Protocol Specific 1Turcot syndrome 1Thrombocytosis 1

Interventions

Surgical Procedures, Operative 1Immunohistochemistry 1Ferrosoferric Oxide 1Erlotinib Hydrochloride 1Congresses as Topic 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Pancreatic Intraductal Neoplasms × Biopsy × Clear all
NCT00482625 2014-10-16

Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery

National Cancer Institute (NCI)

Phase 2 Terminated
6 enrolled 8 charts
Gastrointestinal

Pancreatic Intraductal Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡